{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T20:01:46Z","timestamp":1773345706159,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SYNLAB Holding Deutschland GmbH"},{"name":"Amgen GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diagnosis rates of familial hypercholesterolemia (FH) remain low. We implemented FH ALERT to assess whether alerting physicians for the possibility of FH impacted additional diagnostic activity. The study was conducted from SYNLAB laboratory Weiden (Bavaria). Beyond common reporting of LDL-C or TC, 1411 physicians covering approximately a population of 1.5 million people were eligible to receive an alert letter (AL) including information on FH, if laboratory results exceeded thresholds as follows: adults LDL-C\u2009\u2265\u2009190\u2013250\u00a0mg\/dl (to convert into mmol\/l multiply with 0.0259), TC \u2265\u2009250 to \u2264\u2009310\u00a0mg\/dl (probable suspicion); LDL-C &gt;\u2009250\u00a0mg\/dl and TC &gt;\u2009310\u00a0mg\/dl (strong suspicion). Persons below 18\u00a0years were alerted for LDL-C \u2009140\u00a0mg\/dl and TC \u2265\u2009200\u00a0mg\/dl (strong suspicion). Patients above 60\u00a0years were excluded. Our readouts were characteristics of involved physicians, rate of ALs issued, acceptance, and subsequent diagnostic activity. Physicians were mainly general practitioners in ambulatory care. 75% of the ordered tests were for TC, 25% for LDL-C. We issued 3512 ALs (~\u20095% of tests) triggered by 2846 patients. 86% of eligible physicians stayed with the initiative, 32.7% were alerted, and 70% were positive upon call-center survey. We registered 101 new visitors of <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fhscore.eu\">www.fhscore.eu<\/jats:ext-link> and sent out 93 kits for genetics. Thereof, 26 were returned and 5 patients were positive for FH. Physicians were in general open to our approach. Although genetic testing was taken up with caution, this 3-months pilot examination resulted in a greater rate of patients with FH diagnosed than previous screening projects. Further education on FH in primary care is required to improve FH detection in the community.<\/jats:p>","DOI":"10.1038\/s41598-021-99961-y","type":"journal-article","created":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T10:09:16Z","timestamp":1634206156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["FH ALERT: efficacy of a novel approach to identify patients with familial hypercholesterolemia"],"prefix":"10.1038","volume":"11","author":[{"given":"Felix","family":"Fath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bengeser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Barresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priska","family":"Binner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Fraass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"99961_CR1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference, B. A. et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 38, 2459\u20132472. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144 (2017).","journal-title":"Eur. Heart J."},{"key":"99961_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3238\/arztebl.2014.0523","volume":"111","author":"G Klose","year":"2014","unstructured":"Klose, G., Laufs, U., M\u00e4rz, W. & Windler, E. Familial hypercholesterolemia: developments in diagnosis and treatment. Deutsches Arzteblatt Int. 111, 523\u2013529. https:\/\/doi.org\/10.3238\/arztebl.2014.0523 (2014).","journal-title":"Deutsches Arzteblatt Int."},{"key":"99961_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard, B. G. et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34, 3478\u20133490a. https:\/\/doi.org\/10.1093\/eurheartj\/eht273 (2013).","journal-title":"Eur. Heart J."},{"key":"99961_CR4","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera, A. V. et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J. Am. Coll. Cardiol. 67, 2578\u20132589. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.520 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"99961_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2016.02.009","volume":"247","author":"C Sanna","year":"2016","unstructured":"Sanna, C. et al. Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives. Atherosclerosis 247, 97\u2013104. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.02.009 (2016).","journal-title":"Atherosclerosis"},{"key":"99961_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2017.08.019","volume":"266","author":"N Schmidt","year":"2017","unstructured":"Schmidt, N. et al. Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) study. Atherosclerosis 266, 24\u201330. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.08.019 (2017).","journal-title":"Atherosclerosis"},{"key":"99961_CR7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","volume":"75","author":"SO Beheshti","year":"2020","unstructured":"Beheshti, S. O., Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects. J. Am. Coll. Cardiol. 75, 2553\u20132566. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.057 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"99961_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001236","volume":"3","author":"L Mundal","year":"2014","unstructured":"Mundal, L. et al. Mortality among patients with familial hypercholesterolemia: A registry-based study in Norway, 1992\u20132010. J. Am. Heart Assoc. 3, e001236. https:\/\/doi.org\/10.1161\/JAHA.114.001236 (2014).","journal-title":"J. Am. Heart Assoc."},{"key":"99961_CR9","doi-asserted-by":"publisher","first-page":"a2423","DOI":"10.1136\/bmj.a2423","volume":"337","author":"J Versmissen","year":"2008","unstructured":"Versmissen, J. et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 337, a2423 (2008).","journal-title":"BMJ"},{"key":"99961_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","volume":"72","author":"RR Williams","year":"1993","unstructured":"Williams, R. R. et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72, 171\u2013176. https:\/\/doi.org\/10.1016\/0002-9149(93)90155-6 (1993).","journal-title":"Am. J. Cardiol."},{"key":"99961_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","volume":"303","author":"Scientific Steering Committee on behalf of the Simon Broome Register Group","year":"1991","unstructured":"Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303, 893\u2013896. https:\/\/doi.org\/10.1136\/bmj.303.6807.893 (1991).","journal-title":"BMJ"},{"key":"99961_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1055\/s-2004-822987","volume":"4","author":"JC Defesche","year":"2004","unstructured":"Defesche, J. C., Lansberg, P. J., Umans-Eckenhausen, M. A. & Kastelein, J. J. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin. Vasc. Med. 4, 59\u201365. https:\/\/doi.org\/10.1055\/s-2004-822987 (2004).","journal-title":"Semin. Vasc. Med."},{"key":"99961_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2016.08.037","volume":"253","author":"T Grenkowitz","year":"2016","unstructured":"Grenkowitz, T. et al. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. Atherosclerosis 253, 88\u201393. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.037 (2016).","journal-title":"Atherosclerosis"},{"key":"99961_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg, A. C. et al. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S1-8. https:\/\/doi.org\/10.1016\/j.jacl.2011.04.003 (2011).","journal-title":"J. Clin. Lipidol."},{"key":"99961_CR15","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","volume":"72","author":"AC Sturm","year":"2018","unstructured":"Sturm, A. C. et al. Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel. J. Am. Coll. Cardiol. 72, 662\u2013680. https:\/\/doi.org\/10.1016\/j.jacc.2018.05.044 (2018).","journal-title":"J. Am. Coll. Cardiol."},{"key":"99961_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"AL Catapano","year":"2016","unstructured":"Catapano, A. L. et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253, 281\u2013344. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.018 (2016).","journal-title":"Atherosclerosis"},{"key":"99961_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","author":"F Mach","year":"2019","unstructured":"Mach, F. et al. ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455 (2019).","journal-title":"Eur. Heart J."},{"key":"99961_CR18","unstructured":"Allgemeinmedizin, D. G. f. Haus\u00e4rztliche Risikoberatung zur kardiovaskul\u00e4ren Pr\u00e4vention. S3-Leitlinie. AWMF-Register-Nr. 053-024, DEGAM-Leitlinie Nr. 19. https:\/\/www.degam.de\/files\/Inhalte\/Leitlinien-Inhalte\/Dokumente\/DEGAM-S3-Leitlinien\/053-024_Risikoberatung%20kardiovaskul.%20Praevention\/053-024l_Hausa%CC%88rztliche_Risikoberatung_kardivaskula%CC%88re_Praevention_29-08-2018.pdf (2017).\nAccessed on August 1, 2020."},{"key":"99961_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet. Med."},{"key":"99961_CR20","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/0026-0495(87)90187-9","volume":"36","author":"CM Ballantyne","year":"1987","unstructured":"Ballantyne, C. M., Vega, G. L., East, C., Richards, G. & Grundy, S. M. Low-density lipoprotein metabolism in cerebrotendinous xanthomatosis. Metabolism 36, 270\u2013276. https:\/\/doi.org\/10.1016\/0026-0495(87)90187-9 (1987).","journal-title":"Metabolism"},{"key":"99961_CR21","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1073\/pnas.0508483103","volume":"103","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C. et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA 103, 1810\u20131815. https:\/\/doi.org\/10.1073\/pnas.0508483103 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"99961_CR22","doi-asserted-by":"publisher","first-page":"7397","DOI":"10.1074\/jbc.M110.178368","volume":"286","author":"LJ Wang","year":"2011","unstructured":"Wang, L. J. et al. Molecular characterization of the NPC1L1 variants identified from cholesterol low absorbers. J. Biol. Chem. 286, 7397\u20137408. https:\/\/doi.org\/10.1074\/jbc.M110.178368 (2011).","journal-title":"J. Biol. Chem."},{"key":"99961_CR23","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1001\/jama.298.11.1300","volume":"298","author":"AM Bennet","year":"2007","unstructured":"Bennet, A. M. et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298, 1300\u20131311 (2007).","journal-title":"JAMA"},{"key":"99961_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12944-018-0680-1","volume":"17","author":"LR Wang","year":"2018","unstructured":"Wang, L. R., McIntyre, A. D. & Hegele, R. A. Complex genetic architecture in severe hypobetalipoproteinemia. Lipids Health Dis. 17, 48. https:\/\/doi.org\/10.1186\/s12944-018-0680-1 (2018).","journal-title":"Lipids Health Dis."},{"key":"99961_CR25","doi-asserted-by":"publisher","first-page":"12931","DOI":"10.1074\/jbc.M113.538124","volume":"289","author":"L Argyri","year":"2014","unstructured":"Argyri, L. et al. Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4. J. Biol. Chem. 289, 12931\u201312945. https:\/\/doi.org\/10.1074\/jbc.M113.538124 (2014).","journal-title":"J. Biol. Chem."},{"key":"99961_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0304-3940(99)00129-9","volume":"263","author":"MI Kamboh","year":"1999","unstructured":"Kamboh, M. I. et al. A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer\u2019s disease. Neurosci. Lett. 263, 129\u2013132. https:\/\/doi.org\/10.1016\/s0304-3940(99)00129-9 (1999).","journal-title":"Neurosci. Lett."},{"key":"99961_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2014.02.030","volume":"234","author":"B Hansel","year":"2014","unstructured":"Hansel, B. et al. Premature atherosclerosis is not systematic in phytosterolemic patients: Severe hypercholesterolemia as a confounding factor in five subjects. Atherosclerosis 234, 162\u2013168. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.02.030 (2014).","journal-title":"Atherosclerosis"},{"key":"99961_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.atherosclerosis.2017.05.002","volume":"262","author":"PS Buonuomo","year":"2017","unstructured":"Buonuomo, P. S. et al. Timely diagnosis of sitosterolemia by next generation sequencing in two children with severe hypercholesterolemia. Atherosclerosis 262, 71\u201377. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.05.002 (2017).","journal-title":"Atherosclerosis"},{"key":"99961_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/hmg\/ddt573","volume":"23","author":"AC Alves","year":"2014","unstructured":"Alves, A. C., Etxebarria, A., Soutar, A. K., Martin, C. & Bourbon, M. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia. Hum. Mol. Genet. 23, 1817\u20131828. https:\/\/doi.org\/10.1093\/hmg\/ddt573 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"99961_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1161\/ATVBAHA.113.301505","volume":"33","author":"MM Motazacker","year":"2013","unstructured":"Motazacker, M. M. et al. Evidence of a polygenic origin of extreme high-density lipoprotein cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 33, 1521\u20131528. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301505 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"99961_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","volume":"29","author":"A Pirillo","year":"2017","unstructured":"Pirillo, A. et al. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler. Suppl. 29, 17\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.07.002 (2017).","journal-title":"Atheroscler. Suppl."},{"key":"99961_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","volume":"28","author":"JS Dron","year":"2017","unstructured":"Dron, J. S. & Hegele, R. A. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr. Opin. Lipidol. 28, 161\u2013169. https:\/\/doi.org\/10.1097\/MOL.0000000000000386 (2017).","journal-title":"Curr. Opin. Lipidol."},{"key":"99961_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ymgme.2008.12.014","volume":"96","author":"OL Holla","year":"2009","unstructured":"Holla, O. L. et al. Effects of intronic mutations in the LDLR gene on pre-mRNA splicing: Comparison of wet-lab and bioinformatics analyses. Mol. Genet. Metab. 96, 245\u2013252. https:\/\/doi.org\/10.1016\/j.ymgme.2008.12.014 (2009).","journal-title":"Mol. Genet. Metab."},{"key":"99961_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ajhg.2016.02.024","volume":"98","author":"KN Maxwell","year":"2016","unstructured":"Maxwell, K. N. et al. Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer. Am. J. Hum. Genet. 98, 801\u2013817. https:\/\/doi.org\/10.1016\/j.ajhg.2016.02.024 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"99961_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/cge.13250","volume":"94","author":"O Marmontel","year":"2018","unstructured":"Marmontel, O. et al. Single, short in-del, and copy number variations detection in monogenic dyslipidemia using a next-generation sequencing strategy. Clin. Genet. 94, 132\u2013140. https:\/\/doi.org\/10.1111\/cge.13250 (2018).","journal-title":"Clin. Genet."},{"key":"99961_CR36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2013.01.007","volume":"227","author":"S Bertolini","year":"2013","unstructured":"Bertolini, S. et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis 227, 342\u2013348. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.01.007 (2013).","journal-title":"Atherosclerosis"},{"key":"99961_CR37","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/humu.1380010602","volume":"1","author":"HH Hobbs","year":"1992","unstructured":"Hobbs, H. H., Brown, M. S. & Goldstein, J. L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1, 445\u2013466. https:\/\/doi.org\/10.1002\/humu.1380010602 (1992).","journal-title":"Hum. Mutat."},{"key":"99961_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1399-0004.1998.tb02752.x","volume":"53","author":"S Cassanelli","year":"1998","unstructured":"Cassanelli, S. et al. A \u201cde novo\u201d point mutation of the low-density lipoprotein receptor gene in an Italian subject with primary hypercholesterolemia. Clin. Genet. 53, 391\u2013395. https:\/\/doi.org\/10.1111\/j.1399-0004.1998.tb02752.x (1998).","journal-title":"Clin. Genet."},{"key":"99961_CR39","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli, M. F. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 37, 2315\u20132381. https:\/\/doi.org\/10.1093\/eurheartj\/ehw106 (2016).","journal-title":"Eur. Heart J."},{"key":"99961_CR40","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a","author":"NJ Stone","year":"2013","unstructured":"Stone, N. J. et al. ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation https:\/\/doi.org\/10.1161\/01.cir.0000437738.63853.7a (2013).","journal-title":"Circulation"},{"key":"99961_CR41","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000625","author":"SM Grundy","year":"2018","unstructured":"Grundy, S. M. et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol. Circulation https:\/\/doi.org\/10.1161\/CIR.0000000000000625 (2018).","journal-title":"Circulation"},{"key":"99961_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archinte.163.1.65","volume":"163","author":"MA Umans-Eckenhausen","year":"2003","unstructured":"Umans-Eckenhausen, M. A., Defesche, J. C., van Dam, M. J. & Kastelein, J. J. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch. Intern. Med. 163, 65\u201368 (2003).","journal-title":"Arch. Intern. Med."},{"key":"99961_CR43","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/13548506.2011.644246","volume":"17","author":"L Claassen","year":"2012","unstructured":"Claassen, L., Henneman, L., van der Weijden, T., Marteau, T. M. & Timmermans, D. R. Being at risk for cardiovascular disease: Perceptions and preventive behavior in people with and without a known genetic predisposition. Psychol. Health Med. 17, 511\u2013521. https:\/\/doi.org\/10.1080\/13548506.2011.644246 (2012).","journal-title":"Psychol. Health Med."},{"key":"99961_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2021.02.022","volume":"322","author":"TP Leren","year":"2021","unstructured":"Leren, T. P. & Bogsrud, M. P. Molecular genetic testing for autosomal dominant hypercholesterolemia in 29,449 Norwegian index patients and 14,230 relatives during the years 1993\u20132020. Atherosclerosis 322, 61\u201366. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.02.022 (2021).","journal-title":"Atherosclerosis"},{"key":"99961_CR45","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","volume":"357","author":"MA Umans-Eckenhausen","year":"2001","unstructured":"Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L. & Kastelein, J. J. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 357, 165\u2013168. https:\/\/doi.org\/10.1016\/S0140-6736(00)03587-X (2001).","journal-title":"Lancet"},{"key":"99961_CR46","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.atherosclerosissup.2017.05.015","volume":"30","author":"N Schmidt","year":"2017","unstructured":"Schmidt, N. et al. CaRe high\u2014Cascade screening and registry for high cholesterol in Germany. Atheroscler. Suppl. 30, 72\u201376. https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2017.05.015 (2017).","journal-title":"Atheroscler. Suppl."},{"key":"99961_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2017.11.020","volume":"268","author":"W M\u00e4rz","year":"2018","unstructured":"M\u00e4rz, W. et al. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany. Atherosclerosis 268, 99\u2013107. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.11.020 (2018).","journal-title":"Atherosclerosis"},{"key":"99961_CR48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s00392-017-1193-z","volume":"107","author":"KM Fox","year":"2018","unstructured":"Fox, K. M. et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin. Res. Cardiol. 107, 380\u2013388. https:\/\/doi.org\/10.1007\/s00392-017-1193-z (2018).","journal-title":"Clin. Res. Cardiol."},{"key":"99961_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa047","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: The DA VINCI study. Eur. J. Prev. Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047 (2020).","journal-title":"Eur. J. Prev. Cardiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99961-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99961-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:23:54Z","timestamp":1670084634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-99961-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["99961"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-99961-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Mr. Fath reports employment with SYNLAB Holding Germany GmbH, SYNLAB Academy. SYNLAB Academy received Grants from Amgen GmbH, during the conduct of the project FH ALERT; Grants from Akcea Therapeutics Germany GmbH, outside the submitted work. Dr. Binner, Mr. Bengeser and Mr. Barresi report employment with SYNLAB Holding Germany GmbH, outside the submitted work. Mrs. Schwab reports employment with SYNLAB MCC Human Genetics Mannheim GmbH, outside the submitted work. Dr. Kr\u00e4mer has nothing to disclose. Dr. Fraass is employed by Amgen GmbH and additionally holds stock, outside the submitted work. Dr. M\u00e4rz reports grants and personal fees from AMGEN, Grants and other from SYNLAB Holding Deutschland GmbH, during the conduct of the study; Grants from Siemens Healthineers, Grants and personal fees from Aegerion Pharmaceuticals, Grants and personal fees from AMGEN, grants from Astrazeneca, Grants and personal fees from Sanofi, Grants and personal fees from Alexion Pharmaceuticals, Grants and personal fees from BASF, Grants and personal fees from Abbott Diagnostics, Grants and personal fees from Numares AG, grants and personal fees from Berlin-Chemie, other from SYNLAB Holding Deutschland GmbH, Grants and personal fees from Akcea Therapeutics, Grants from Bayer Vital GmbH , grants from bestbion dx Gmbh, grants from Boehringer Ingelheim Pharma GmbH Co KG, grants from Immundiagnostik GmbH, Grants from Merck Chemicals GmbH, Grants from MSD Sharp and Dohme GmbH, Grants and personal fees from Novartis Pharma GmbH, Grants from Olink Proteomics, outside the submitted work. Dr. Ray reports receiving investigator initiated research Grants to his institution from Amgen, Sanofi, Regeneron, MSD, Pfizer, Daiichi Sankyo and honoraria for consultancy from Amgen, Sanofi, Regeneron, MSD, Pfizer, Astra Zeneca, Lilly, Medicines Company, Kowa, IONIS, Takeda, Novo Nordisk, Boehringer Ingelheim, Esperion, Cipla, Algorithm, Abbvie, Resverlogix, Cerenis, Novartis, Akcea, Silence Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20421"}}